AL Amyloidosis Clinical Trial
Official title:
A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
The purpose of this protocol is to generate a registry of Chinese patients with AL amyloidosis treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy.
| Status | Recruiting |
| Enrollment | 500 |
| Est. completion date | September 2025 |
| Est. primary completion date | March 2025 |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - 18 years and older - newly diagnosed or refractory/relapsed AL amyloidosis - treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy Exclusion Criteria: - co-diagnosis of multiple myeloma or Waldenström's macroglobulinemia |
| Country | Name | City | State |
|---|---|---|---|
| China | Peking Union Medical College Hospital | Beijing |
| Lead Sponsor | Collaborator |
|---|---|
| Peking Union Medical College Hospital |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Hematologic complete response at 3 months | 3 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05451771 -
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
|
Phase 1/Phase 2 | |
| Completed |
NCT02574676 -
Quality of Life (QOL) Registry for Patients With AL Amyloidosis
|
||
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Active, not recruiting |
NCT05199337 -
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01758042 -
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
|
N/A | |
| Completed |
NCT01409148 -
Radioimmunoimaging of AL Amyloidosis
|
Phase 1 | |
| Active, not recruiting |
NCT04512235 -
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis
|
Phase 3 | |
| Recruiting |
NCT06383143 -
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
|
||
| Completed |
NCT02632786 -
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
|
Phase 2 | |
| Completed |
NCT02841033 -
Daratumumab for the Treatment of Patients With AL Amyloidosis
|
Phase 1/Phase 2 | |
| Completed |
NCT04304144 -
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
|
Phase 2 | |
| Recruiting |
NCT01408225 -
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
|
||
| Recruiting |
NCT04895917 -
Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis
|
Phase 2 | |
| Terminated |
NCT02489500 -
Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
|
Phase 3 | |
| Completed |
NCT01570387 -
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
|
Phase 1/Phase 2 | |
| Terminated |
NCT03154047 -
Study in Subjects With Light Chain (AL) Amyloidosis
|
Phase 2 | |
| Completed |
NCT03236792 -
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04392960 -
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
|
N/A | |
| Recruiting |
NCT05898646 -
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
|
Phase 2 | |
| Not yet recruiting |
NCT06022939 -
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
|
Phase 3 |